FDA Proposes Stripping Gender from Regulations
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA proposed a rule to eliminate the term “gender” from its regulations, citing a 2025 executive order from President Trump that mandates a focus on “biological sex.”
- President Trump’s 2025 executive order underpins the FDA’s move, reflecting the administration’s push to recognize only two biological sexes across federal policy.
- FDA stated the proposal “does not impact industry practice” and does not anticipate any measurable change for drug manufacturers.
- Legal experts warned the rule potentially broadens drug‑testing requirements and affects representation of gender‑minority participants in clinical trials.
Why it matters: Gender‑minority researchers risk losing regulatory recognition, limiting drug‑trial enrollment for trans and non‑binary patients, while the pharmaceutical industry faces future compliance adjustments without immediate cost changes.
